Received Jul 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 1 | — | IM |
swelling; redness; blisters; pain; severe discomfort; blue/purple discoloration affecting the toes only; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (swelling), ERYTHEMA (redness), BLISTER (blisters), PAIN (pain) and DISCOMFORT (severe discomfort) in a 9-decade-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below. No Medical History information was reported. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced SWELLING (swelling), ERYTHEMA (redness), BLISTER (blisters), PAIN (pain), DISCOMFORT (severe discomfort) and SKIN DISCOLOURATION (blue/purple discoloration affecting the toes only). At the time of the report, SWELLING (swelling), ERYTHEMA (redness), BLISTER (blisters), PAIN (pain), DISCOMFORT (severe discomfort) and SKIN DISCOLOURATION (blue/purple discoloration affecting the toes only) had not resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) was unknown. Vaccines within the past 4 weeks and medical conditions were reported as none. Concomitant medication details were not provided. It was reported that the patient had persistent symptoms that began after receiving the first Moderna COVID-19 vaccine six years ago. It was unknown if the patient experienced any additional symptoms/events. It was reported that the symptoms had persisted despite evaluations by multiple healthcare providers, biopsies, topical creams, and medications, without improvement.